Clinical Roundup Alcohol-attributable cancer deaths in the U.S. doubled between 1990 and 2023, Sylvester-led study shows September 11, 2026Vol.52 No.33
Clinical Roundup Zipalertinib + chemo meets primary endpoint in phase III REZILIENT3 trial in first-line EGFR exon 20 insertion mutation NSCLC September 11, 2026Vol.52 No.33
Clinical Roundup Dietary supplement glutamine + standard therapy improved outcomes in advanced pancreatic cancer, Cedars-Sinai investigators find September 11, 2026Vol.52 No.33
Clinical Roundup Botensilimab + balstilimab showed no CRC recurrences in resectable colon cancer, phase II NEST trial shows September 11, 2026Vol.52 No.33
Clinical Roundup Blood cancer patients may have broader stem cell donor options than previously thought, ACCESS trial shows September 11, 2026Vol.52 No.33
Clinical Roundup Penn Medicine launches first human clinical trial to test precision form of FLASH proton therapy September 11, 2026Vol.52 No.33
Clinical Roundup New framework developed for treating liver cancer by UT Southwestern-led research could lead to updated standards September 11, 2026Vol.52 No.33
Clinical RoundupFree Traditional prostate cancer risk factors do not predict hormone therapy benefit, UCLA-led study finds August 14, 2026Vol.52 No.32
Clinical RoundupFree Half of prostate cancer focal therapy use falls outside current guideline-supported patient groups, study finds August 14, 2026Vol.52 No.32
Clinical RoundupFree HCC-LIVE consortium publishes treatment framework for hepatocellular carcinoma August 14, 2026Vol.52 No.32
